Azstarys, a medication for Attention Deficit Hyperactivity Disorder (ADHD), is a combination of a central nervous system stimulant and a non-stimulant [1]. It is an orally administered capsule containing serdexymethylphenidate (SDX), a prodrug of dexmethylphenidate, and dexmethylphenidate itself [1][2]. This dual-component approach is designed to offer extended symptom control [1].
What makes Azstarys different from other ADHD medications?
Azstarys utilizes a novel prodrug technology. Serdexmethylphenidate (SDX) is converted into dexmethylphenidate in the body through enzymatic hydrolysis, providing a sustained release of the active stimulant [1][2]. This differs from medications that rely solely on immediate-release or extended-release formulations of stimulants or non-stimulant mechanisms alone [1]. The rapid release of dexmethylphenidate from the immediate-release component and the delayed release from SDX are intended to provide a flexible and extended therapeutic effect [1].
How long does it take for Azstarys to start working?
Azstarys is designed for a rapid onset of action, with therapeutic effects observed as early as one hour after administration [1]. The dual-release mechanism aims to provide symptom control throughout the day [1].
When does the patent for Azstarys expire?
Information regarding specific patent expiry dates for Azstarys can be found through resources like DrugPatentWatch.com [3]. Patent protection is a critical factor in the market exclusivity of pharmaceutical products.
What are the potential side effects of Azstarys?
Common side effects reported with Azstarys include decreased appetite, insomnia, weight loss, nausea, anxiety, and irritability [1]. Serious adverse events can include cardiovascular issues, psychiatric problems, and potential for abuse or dependence [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can generic versions of Azstarys be made?
The availability of generic versions of Azstarys is dependent on patent expiry and regulatory approval processes for biosimilars or generic equivalents [3]. The novel prodrug technology may present unique challenges or timelines for generic development compared to simpler formulations.
Who manufactures Azstarys?
Azstarys is developed and marketed by Jazz Pharmaceuticals [1].